Immunotherapy plus chemo shows promise against stomach cancer in early trial

NCT ID NCT06808971

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding the immunotherapy drug adebrelimab to standard chemotherapy can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 61 participants will receive the drug combination before and after surgery. The main goal is to see how many patients have no cancer cells left in their tumor after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: adebrelimab (an immunotherapy drug) combined with nab-paclitaxel, oxaliplatin, and tegafur gimeracil oteracil potassium capsule (chemotherapy drugs)
What this could lead to: If this works, it could offer a more effective treatment approach for locally advanced stomach cancer, potentially increasing the chance of no cancer remaining after surgery.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 61 participants, so results may not apply to everyone. The combination of drugs may cause significant side effects, and it's not yet known if it improves long-term survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC ADENOCARCINOMA GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.